Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Piotroski F-Score: 5 (As of Jun. 27, 2026) — 17% Below Median


XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
100 GF Score
Price €58.60
GF Value €50.93
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Piotroski F-Score?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -1.10% 100 Piotroski F-Score is 5 as of Jun. 27, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates XMAD:ROVI with a GF Score™ of 100/100 and a GF Value™ of €50.93 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 981 Drug Manufacturers companies, Laboratorios Farmaceuticos Rovi ranks better than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Laboratorios Farmaceuticos Rovi has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Piotroski F-Score or its related term are showing as below:

XMAD:ROVI' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Laboratorios Farmaceuticos Rovi was 8. The lowest was 3. And the median was 6.

Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Laboratorios Farmaceuticos Rovi Piotroski F-Score Related Terms


Laboratorios Farmaceuticos Rovi Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Piotroski F-Score Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 7.00 5.00 7.00 6.00

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 6.00 6.00 5.00

XMAD:ROVI vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Piotroski F-Score falls into.


XMAD:ROVI
100GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 21.635 + 58.029 + 42.677 + 9.479 = €131.8 Mil.
Cash Flow from Operations was 9.18 + 73.373 + 85.681 + 12.959 = €181.2 Mil.
Revenue was 159.698 + 210.473 + 218.42 + 152.494 = €741.1 Mil.
Gross Profit was 105.285 + 147.813 + 139.19 + 92.885 = €485.2 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(813.963 + 869.605 + 922.069 + 955.691 + 926.315) / 5 = €897.5286 Mil.
Total Assets at the begining of this year (Mar25) was €814.0 Mil.
Long-Term Debt & Capital Lease Obligation was €86.7 Mil.
Total Current Assets was €539.3 Mil.
Total Current Liabilities was €147.5 Mil.
Net Income was 29.384 + 69.147 + 92.536 + 18.101 = €209.2 Mil.

Revenue was 178.161 + 235.276 + 434.413 + 154.892 = €1,002.7 Mil.
Gross Profit was 110.315 + 163.313 + 282.361 + 90.398 = €646.4 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(778.663 + 857.325 + 877.848 + 832.022 + 813.963) / 5 = €831.9642 Mil.
Total Assets at the begining of last year (Mar24) was €778.7 Mil.
Long-Term Debt & Capital Lease Obligation was €85.3 Mil.
Total Current Assets was €467.9 Mil.
Total Current Liabilities was €126.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Laboratorios Farmaceuticos Rovi's current Net Income (TTM) was 131.8. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Laboratorios Farmaceuticos Rovi's current Cash Flow from Operations (TTM) was 181.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=131.82/813.963
=0.16194839

ROA (Last Year)=Net Income/Total Assets (Mar24)
=209.168/778.663
=0.26862455

Laboratorios Farmaceuticos Rovi's return on assets of this year was 0.16194839. Laboratorios Farmaceuticos Rovi's return on assets of last year was 0.26862455. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Laboratorios Farmaceuticos Rovi's current Net Income (TTM) was 131.8. Laboratorios Farmaceuticos Rovi's current Cash Flow from Operations (TTM) was 181.2. ==> 181.2 > 131.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=86.668/897.5286
=0.09656294

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=85.268/831.9642
=0.10248999

Laboratorios Farmaceuticos Rovi's gearing of this year was 0.09656294. Laboratorios Farmaceuticos Rovi's gearing of last year was 0.10248999. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=539.279/147.53
=3.65538535

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=467.855/126.277
=3.70498982

Laboratorios Farmaceuticos Rovi's current ratio of this year was 3.65538535. Laboratorios Farmaceuticos Rovi's current ratio of last year was 3.70498982. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Laboratorios Farmaceuticos Rovi's number of shares in issue this year was 51.149. Laboratorios Farmaceuticos Rovi's number of shares in issue last year was 51.145. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=485.173/741.085
=0.65467929

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=646.387/1002.742
=0.64461945

Laboratorios Farmaceuticos Rovi's gross margin of this year was 0.65467929. Laboratorios Farmaceuticos Rovi's gross margin of last year was 0.64461945. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=741.085/813.963
=0.91046522

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1002.742/778.663
=1.28777404

Laboratorios Farmaceuticos Rovi's asset turnover of this year was 0.91046522. Laboratorios Farmaceuticos Rovi's asset turnover of last year was 1.28777404. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Laboratorios Farmaceuticos Rovi has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Piotroski F-Score of 5 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Laboratorios Farmaceuticos Rovi's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #379 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Laboratorios Farmaceuticos Rovi's Piotroski F-Score too high?
Laboratorios Farmaceuticos Rovi's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Laboratorios Farmaceuticos Rovi's value of 5 is 0% at this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #379 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 100/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #379 out of 981 companies for Piotroski F-Score. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Laboratorios Farmaceuticos Rovi's value of 5 is 0% at this benchmark. Historically, Laboratorios Farmaceuticos Rovi's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Laboratorios Farmaceuticos Rovi has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €50.93, compared to a current price of €58.60 — trading 15.1% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Piotroski F-Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €58.60 is trading 15.1% above its estimated GF Value™ of €50.93. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Modestly Overvalued.

Key valuation signals for XMAD:ROVI:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: €50.93 vs. price of €58.60 (15.1% above fair value)
  • GF Score™: 100/100 with 1 warning sign
  • Industry Position: 0% at the Drug Manufacturers median (#379 of 981)

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
100GF Score

Get the complete analysis for XMAD:ROVI

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.60
Price
€50.93
GF Value